Assessing Surgery Partners (SGRY) Valuation After Optimistic Sentiment Ahead Of Fourth Quarter Results
Shares of Surgery Partners (SGRY) recently climbed 7.7% on heavy trading, driven by anticipation for fourth-quarter 2025 results and modestly higher revenue expectations. Despite this recent optimism, the company's longer-term returns have been relatively weak. The stock is currently trading at US$15.46, which is significantly undervalued compared to the fair value estimate of $25.45, suggesting potential for growth through disciplined execution, M&A, and margin expansion.
Assessing Surgery Partners (SGRY) Valuation After Optimistic Sentiment Ahead Of Fourth Quarter Results
Surgery Partners (SGRY) shares recently surged by 7.7% on optimistic sentiment ahead of its Q4 2025 results, despite weaker long-term returns. The article suggests SGRY is undervalued at $15.46 compared to a fair value estimate of $25.45, with potential for margin expansion and improved cash flow from disciplined M&A. However, rising interest expenses or slow acquisitions could impact this positive outlook.
Surgery Partners, Inc. (NASDAQ:SGRY) Receives Consensus Rating of "Moderate Buy" from Analysts
Analysts have given Surgery Partners, Inc. (NASDAQ:SGRY) a consensus "Moderate Buy" rating, with an average 12-month price target of $27.11, despite the company recently missing quarterly EPS estimates and reporting a negative net margin. Shares are currently trading around $15, and institutional investors like Pentwater Capital Management and UBS Group have significantly increased their stakes in the company. Surgery Partners operates as a healthcare services provider specializing in ambulatory surgery centers and surgical hospitals across the United States.
Surgery Partners stock hits 52-week low at $14.02
Surgery Partners Inc. (SGRY) stock reached a 52-week low of $14.02, reflecting a 45.52% decline over the past year due to market conditions and volatility. Despite generating $3.29 billion in revenue with 10.14% growth, the company reported a loss of $1.35 per share, though analysts predict a return to profitability this year. Recent developments include Q3 2025 financial results, a new partnership, bond offerings, and leadership changes, while analysts have lowered price targets due to payer mix concerns.
Surgery Partners stock hits 52-week low at $14.93
Surgery Partners (SGRY) stock has dropped to a new 52-week low of $14.93, marking a significant 41.55% decline over the past year. Despite recent challenges, InvestingPro analysis suggests the company's net income is expected to grow this year, with a forecasted return to profitability and a strong free cash flow yield of 10%. Recent developments include reporting Q3 2025 financial results, strategic partnerships, new senior unsecured notes, updated analyst price targets, and a new Chief Operating Officer.
Cash Machine Trading Cheap – Surgery Partners Stock Set to Run?
Surgery Partners (SGRY) stock is presented as a compelling investment due to its growth, cash production, and significant valuation discount despite recent setbacks. The company demonstrated strong Q3 2025 performance with increased surgical cases and operating cash flow, along with promising fundamentals like a high cash flow yield and revenue growth. However, the article also highlights the stock's history of significant drawdowns during market corrections, indicating high downside risk.
Surgery Partners, Inc. (NASDAQ:SGRY) Given Average Rating of "Moderate Buy" by Analysts
Surgery Partners, Inc. (NASDAQ:SGRY) has received a consensus "Moderate Buy" rating from analysts, with an average 12-month price target of $27.11. Despite missing quarterly EPS estimates and having a negative net margin, large institutional investors, including Pentwater Capital Management, Vanguard Group, and UBS Group AG, have significantly increased their holdings in the company. The stock currently trades around $15.90, below analyst targets, with a market capitalization of $2.06 billion.
Is Surgery Partners Inc the Silent Healthcare Cheat Code Wall Street Slept On?
The article explores Surgery Partners Inc (SGRY) as a potentially undervalued investment opportunity in the healthcare sector, focusing on its strategy of shifting medical procedures from traditional hospitals to more cost-effective outpatient surgery centers. It discusses the company's business model, growth potential through scaling and partnerships, and risk factors like debt and regulatory changes. The author concludes that SGRY could be a "conditional cop" for investors comfortable with volatility and healthcare-specific risks, but not for those seeking a low-drama investment.
Surgery Partners prices $425M senior notes offering
Surgery Partners announced the pricing of its offering of $425 million in 7.750% senior notes due 2030 at par. The offering is expected to close on January 19, 2026, subject to customary closing conditions. The company plans to use the net proceeds, along with cash on hand, to redeem all of its outstanding 10.000% senior notes due 2027.
Sivik Global Healthcare LLC Purchases 95,000 Shares of Surgery Partners, Inc. $SGRY
Sivik Global Healthcare LLC significantly increased its stake in Surgery Partners, Inc. (NASDAQ:SGRY) by 76%, acquiring an additional 95,000 shares to bring its total holding to 220,000 shares, now valued at approximately $4.76 million. Despite this increased institutional interest, Surgery Partners recently missed its quarterly EPS estimates, reporting $0.13 against an anticipated $0.19, and analysts have adjusted price targets downwards while maintaining a "Moderate Buy" rating with an average target of $27.11. The company's stock currently trades around $15.60, with a market capitalization of $2.02 billion.
RBC Capital and Mizuho Securities Stay Bullish on Surgery Partners (SGRY)
RBC Capital and Mizuho Securities have maintained a bullish outlook on Surgery Partners (SGRY). RBC Capital reiterated its Buy rating with a $31 price target, citing strong long-term growth prospects, while Mizuho Securities, despite lowering its price target to $19, kept an Outperform rating, expecting 2026 to be a "pivotal year" for the healthcare sector with improved margins. Surgery Partners operates a network of over 200 healthcare facilities across 30 states.
Surgery Partners, Inc. $SGRY Stake Lessened by Voya Investment Management LLC
Voya Investment Management LLC significantly reduced its stake in Surgery Partners, Inc. (SGRY) by 86.5% during the third quarter, selling 88,405 shares and retaining 13,842 shares valued at $300,000. Despite this, other institutions exhibited mixed activity, with some materially increasing or initiating positions. Surgery Partners missed Q3 earnings estimates, reporting $0.13 EPS against an anticipated $0.19, leading analysts to trim price targets while maintaining a "Moderate Buy" consensus.
Surgery Partners, Inc. (SGRY) Stock Analysis: Exploring a 65.94% Upside Potential Amid Sector Growth
Surgery Partners, Inc. (SGRY) is analyzed as an attractive investment in the healthcare sector, with a current trading price of $15.34 and an average analyst target price of $25.45, indicating a 65.94% upside potential. Despite current negative EPS due to reinvestment, the company shows solid revenue growth and strong free cash flow, supported by bullish analyst sentiment. Its focus on ambulatory surgical centers positions it well for future growth in the evolving healthcare landscape.
ATTENTION Surgery Partners, Inc. (SGRY) Investors: Possible Fraud - Contact Levi & Korsinsky Today
Levi & Korsinsky has initiated an investigation into Surgery Partners, Inc. (SGRY) for potential violations of federal securities laws after the company lowered its full-year revenue and adjusted EBITDA guidance. Following this announcement, attributed to delays in capital deployment and a cautious outlook on payer mix, Surgery Partners' stock price fell by over 25%. The firm is inviting investors who suffered losses to contact them to explore potential recovery options.
Surgery Partners Inc (SGRY) Is Quietly Exploding – Are You Sleeping On This Stock?
Surgery Partners Inc (SGRY) is gaining attention as a potential high-growth healthcare stock, aiming to shift surgical procedures from traditional hospitals to cheaper, faster outpatient centers. The article explores SGRY's business model, growth strategy, and risk factors, comparing it to competitors like United Surgical Partners International. It concludes that while SGRY presents a high-upside opportunity for aggressive investors due to its focus on the growing outpatient surgery trend, it also involves significant volatility and complexity.
Surgery Partners Inc (SGRY) Is Quietly Exploding – Are You Sleeping On This Stock?
Surgery Partners Inc (SGRY) is generating buzz among investors and is positioned as a significant player in the outpatient surgery market, aiming to shift procedures from traditional hospitals to cheaper and faster centers. The company faces high growth potential due to this industry trend but also carries volatility and risks associated with healthcare regulation and competition. Investors are advised to consider its high-upside, high-complexity nature, making it a "watchlist first, cop later" stock for most, though aggressive growth investors might find it a calculated risk.
Surgery Partners, Inc. (NASDAQ:SGRY) Given Average Recommendation of "Moderate Buy" by Brokerages
Surgery Partners, Inc. (NASDAQ:SGRY) has received a consensus "Moderate Buy" rating from ten brokerages, with an average 12-month price target of $27.11, despite some recent price target reductions by firms like Benchmark, Barclays, JPMorgan, and UBS. The company recently missed Q3 EPS and revenue estimates, reporting a negative net margin of 5.21% but 6.6% year-over-year revenue growth. SGRY shares opened at $15.53, trading below its 50-day and 200-day moving averages, and analysts project $0.67 EPS for the current year.
Mizuho Securities Reaffirm Bullish Stance on Surgery Partners (SGRY)
Mizuho Securities reaffirmed its Buy rating on Surgery Partners (SGRY) with a $19 price target, citing a positive 2026 forecast for managed care and health facilities. Analyst Ann Hynes expects improved margins due to a commercial turnaround, particularly in Medicaid and Medicare. The stock has a consensus target price of $26.30 from 11 analysts, offering an estimated 67.5% upside potential.
Mizuho Securities Reaffirm Bullish Stance on Surgery Partners (SGRY)
Mizuho Securities analyst Ann Hynes has reiterated a Buy rating for Surgery Partners (SGRY), setting a price target of $19, indicating a 21% upside. The bullish outlook is based on a positive 2026 forecast for managed care and health facilities, with Hynes anticipating improved margins in the coming years, particularly in Medicaid and Medicare. The stock has received Buy ratings from eight out of eleven analysts, with a consensus target price of $26.30, suggesting an estimated 67.5% upside potential.
Mizuho Securities Reaffirm Bullish Stance on Surgery Partners (SGRY)
Mizuho Securities analyst Ann Hynes has reiterated a Buy rating on Surgery Partners (SGRY) with a price target implying a 21% upside. This bullish outlook is driven by a positive 2026 forecast for the managed care and health facilities sector, anticipating improved margins in Medicaid and Medicare. The company, which provides surgical and ancillary services, has received Buy ratings from 8 out of 11 analysts, with a consensus target price of $26.30 indicating significant upside potential.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Surgery Partners, Inc. - SGRY
Pomerantz LLP is investigating potential securities fraud claims against Surgery Partners, Inc. (NASDAQ: SGRY) following a significant drop in its stock price. This investigation stems from the company's lowered full-year revenue and adjusted EBITDA guidance for 2025, which it attributed to capital deployment delays, divestitures, and a cautious outlook on commercial payer mix and volume. Investors are encouraged to contact the law firm for information on joining the class action.
Squarepoint Ops LLC Cuts Stock Position in Surgery Partners, Inc. $SGRY
Squarepoint Ops LLC significantly reduced its stake in Surgery Partners (NASDAQ:SGRY) by 74.5% during Q2, selling 154,971 shares and retaining 53,066 shares valued at $1.18 million. Surgery Partners missed Q3 earnings and revenue estimates and reported a negative net margin, despite a 6.6% year-over-year revenue growth. Analysts maintain a "Moderate Buy" consensus with an average price target of $27.11, while the stock currently trades around $15.70.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Surgery Partners, Inc. - SGRY
Pomerantz LLP is investigating potential claims of securities fraud or unlawful business practices against Surgery Partners, Inc. on behalf of investors. This investigation follows a significant drop in Surgery Partners' stock price after the company lowered its full-year revenue and adjusted EBITDA guidance due to timing delays in capital deployment, asset divestitures, and a cautious outlook on commercial payer mix and volume. Investors impacted by the stock price decline are encouraged to contact Pomerantz LLP.
Protect Your Investment: Contact Levi & Korsinsky About the Surgery Partners, Inc. (SGRY) Investigation
Levi & Korsinsky has launched an investigation into Surgery Partners, Inc. (SGRY) following a significant stock price drop. The investigation concerns potential violations of federal securities laws after the company lowered its full-year revenue and adjusted EBITDA guidance. Shareholders who experienced losses are encouraged to contact Levi & Korsinsky to explore potential recovery options.
Surgery Partners (SGRY): Reassessing Valuation After Guidance Cut, Legal Probe, and Analyst Target Reductions
Surgery Partners (SGRY) faces reassessment after a guidance cut, legal probe, and analyst downgrades highlight a 25% stock slide and fading momentum. Despite a narrative of being 38.5% undervalued with an implied fair value of $25.73, risks from rising interest costs and slower acquisitions could derail a valuation re-rating. Investors are debating if current discounts fully account for future growth challenges or if it's an early entry point.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Surgery Partners, Inc. - SGRY
Pomerantz LLP is investigating potential securities fraud claims against Surgery Partners, Inc. following a significant drop in its stock price. The investigation stems from the company's lowered full-year revenue and adjusted EBITDA guidance, announced on November 10, 2025, which led to a 25.42% stock decline. Investors are encouraged to contact the law firm regarding their potential claims.
Surgery Partners (SGRY) Is Down 10.9% After $425M Debt Raise And Baylor Partnership - What's Changed
Surgery Partners, Inc. recently completed a $425 million debt offering and established a partnership with Baylor Scott & White Health to operate a surgical hospital in Bryan, Texas. This move aims to strengthen liquidity and expand its presence in high-acuity outpatient care. The article analyzes how these developments impact Surgery Partners' growth outlook and investment narrative, especially considering increased interest costs against current negative earnings and cash flow.
Surgery Partners (NASDAQ:SGRY) Price Target Cut to $19.00 by Analysts at Mizuho
Mizuho reduced its price target for Surgery Partners (NASDAQ:SGRY) to $19.00 from $22.00, maintaining an "outperform" rating, which suggests a potential upside of over 20%. This adjustment comes alongside other analysts also trimming their targets, contributing to a consensus "Moderate Buy" rating with an average price target of $27.11. The company recently missed its quarterly EPS estimate and posted a negative net margin despite a 6.6% year-over-year revenue increase.
Surgery Partners Issues $425M Senior Notes for Flexibility
Surgery Partners, through its subsidiary Surgery Center Holdings, Inc., issued an additional $425 million in 7.250% Senior Notes due 2032 to enhance financial flexibility and market positioning. While the company shows strong revenue growth and operational efficiencies, it faces profitability challenges and weak technical indicators, leading TipRanks' AI Analyst Spark to rate SGRY as "Neutral." The stock has a $16.50 price target from analysts.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Surgery Partners, Inc. - SGRY
Pomerantz LLP is investigating potential securities fraud claims against Surgery Partners, Inc. (NASDAQ:SGRY) after the company lowered its full-year revenue and adjusted EBITDA guidance. This guidance revision, attributed to capital deployment delays, divestitures, and a cautious outlook on commercial payer mix, caused Surgery Partners' stock price to drop significantly by 25.42%. Investors affected by this stock price decline are encouraged to contact Pomerantz LLP for information regarding a potential class action.
Surgery Partners (SGRY) Is Down 10.9% After $425M Debt Raise And Baylor Partnership - What's Changed
Surgery Partners recently completed a $425 million debt raise and partnered with Baylor Scott & White Health for a new surgical hospital, signaling an expansion into higher-acuity outpatient care. While these moves strengthen liquidity and align with the company's growth strategy in outpatient surgery, the added debt increases interest costs, posing a challenge to profitability amidst negative earnings and cash flow. Investors are evaluating how this new capital will drive volume growth and margin improvements, keeping in mind the increased leverage.
2 Healthcare Stocks on Our Watchlist and 1 We Brush Off
This article evaluates three healthcare stocks, recommending two for investors' watchlists and one to avoid. Surgery Partners (SGRY) is identified as a stock to sell due to disappointing sales, low free cash flow, and high debt. ResMed (RMD) and Inspire Medical Systems (INSP) are highlighted as strong contenders because of their consistent growth, profitability, and increasing free cash flow margins.
Surgery Partners Issues $425M Senior Notes for Flexibility
Surgery Partners (SGRY) subsidiary, Surgery Center Holdings, Inc., issued an additional $425 million in 7.250% Senior Notes due 2032, aiming to boost financial flexibility. The issuance is part of an existing series and comes despite the company's "Hold" rating with a $16.50 price target from analysts, and a "Neutral" rating from TipRanks' AI Analyst, Spark, due to profitability challenges. Spark noted strong revenue growth and operational efficiencies but weak technical indicators and poor valuation.
Protect Your Investment: Contact Levi & Korsinsky About the Surgery Partners, Inc. (SGRY) Investigation
Levi & Korsinsky has initiated an investigation into Surgery Partners, Inc. (NASDAQ: SGRY) following a significant drop in its stock price. The investigation concerns potential violations of federal securities laws after the company lowered its full-year revenue and adjusted EBITDA guidance for 2025, leading to a 25% stock price decline on November 10, 2025. Investors who suffered losses on SGRY securities are encouraged to contact Levi & Korsinsky to explore potential recovery options.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Surgery Partners, Inc. - SGRY
Pomerantz LLP is investigating potential securities fraud claims against Surgery Partners, Inc. (NASDAQ:SGRY) after the company lowered its full-year revenue and adjusted EBITDA guidance for 2025. This revision, attributed to capital deployment delays, divestitures, and a cautious outlook on commercial payer mix, led to a 25.42% drop in Surgery Partners' stock price on November 10, 2025. Investors are encouraged to contact Pomerantz LLP for information regarding joining a potential class action.
Surgery Partners subsidiary prices $425M add-on notes
A subsidiary of Surgery Partners (NASDAQ:SGRY) has priced $425 million in add-on notes. The additional notes, due in 2031, will be issued at 100% of their face value.
Lost Money on Surgery Partners, Inc. (SGRY)? Contact Levi & Korsinsky About Fraud Investigation
Levi & Korsinsky has initiated an investigation into Surgery Partners, Inc. (SGRY) following a significant drop in its stock price after the company lowered its full-year revenue and adjusted EBITDA guidance for 2025. This guidance revision was attributed to capital deployment delays, lost earnings from divestitures, and a cautious outlook on commercial payer mix and volume. Investors who suffered losses on their Surgery Partners securities are encouraged to contact Levi & Korsinsky for a potential recovery under federal securities laws.
Lost Money on Surgery Partners, Inc. (SGRY)? Contact Levi & Korsinsky About Fraud Investigation
Levi & Korsinsky has launched an investigation into Surgery Partners, Inc. (NASDAQ: SGRY) following a significant 25% stock drop on November 10, 2025. This investigation concerns potential violations of federal securities laws after Surgery Partners lowered its full-year revenue and adjusted EBITDA guidance due to capital deployment delays, lost earnings from divestitures, and a cautious outlook on commercial payer mix. Investors who suffered losses on their SGRY securities are encouraged to contact Levi & Korsinsky for a potential recovery.
Caxton Associates LLP Decreases Stock Holdings in Surgery Partners, Inc. $SGRY
Caxton Associates LLP significantly reduced its stake in Surgery Partners, Inc. (NASDAQ:SGRY) by 43.5% in the second quarter, selling 79,594 shares and now holding 103,589 shares valued at $2.30 million. This move comes as Surgery Partners missed EPS and revenue estimates, shows a negative net margin and P/E, and trades near its 52-week low despite some revenue growth. Despite trimmed price targets from several brokers, the analyst consensus remains a "Moderate Buy" with an average price target of $27.44.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Surgery Partners, Inc. - SGRY
Pomerantz LLP is investigating potential securities fraud claims against Surgery Partners, Inc. (NASDAQ: SGRY) following a significant drop in its stock price. The investigation stems from Surgery Partners lowering its full-year revenue and adjusted EBITDA guidance on November 10, 2025, which led to a 25.42% stock price fall. Investors are encouraged to contact Pomerantz LLP for information regarding a potential class action lawsuit.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Surgery Partners, Inc. - SGRY
Pomerantz LLP is investigating potential securities fraud claims against Surgery Partners, Inc. (NASDAQ: SGRY) on behalf of its investors. This investigation follows a significant drop in the company's stock price after it lowered its full-year revenue and adjusted EBITDA guidance for 2025, attributing the revision to capital deployment delays, divestitures, and a cautious outlook on commercial payer mix and volume. Investors are encouraged to contact the firm regarding their potential claims.
SGRY ALERT: Levi & Korsinsky Investigates Surgery Partners, Inc. on Behalf of Shareholders Who Lost Money
Levi & Korsinsky is investigating Surgery Partners, Inc. (NASDAQ: SGRY) due to potential violations of federal securities laws. This investigation follows a more than 25% drop in Surgery Partners' stock price on November 10, 2025, after the company lowered its full-year revenue and adjusted EBITDA guidance. Shareholders who have lost money may be eligible to obtain additional information from the firm.
AYAL Capital Advisors Ltd Invests $2.78 Million in Surgery Partners, Inc. $SGRY
AYAL Capital Advisors Ltd has acquired a new stake of 125,000 shares in Surgery Partners, Inc. (NASDAQ:SGRY), valued at approximately $2.78 million, representing 0.10% of the company. Despite recent analyst price target cuts, the consensus rating remains a "Moderate Buy" with an average price target of $27.44. Surgery Partners recently missed quarterly EPS and revenue estimates, and the stock is currently trading near its 52-week low.
Did Surgery Partners, Inc. (SGRY) Mislead Investors? Levi & Korsinsky Investigates
Levi & Korsinsky is investigating Surgery Partners, Inc. (SGRY) for potential violations of federal securities laws after the company lowered its full-year revenue and adjusted EBITDA guidance for 2025. The revised guidance, attributed to capital deployment delays, divestitures, and cautious payer mix, led to a 25% stock price drop. The firm is inviting affected investors to contact them for more information.
Surgery Partners, Inc. Announces Pricing of Add-On Notes Offering
Surgery Partners, Inc. (SGRY) announced the pricing of a $425 million offering of 7.250% senior unsecured notes due 2032. The proceeds will be used for general corporate purposes, including debt repayment. The offering is expected to close on December 16, 2025.
Surgery Partners, Inc. Announces Pricing of Add-On Notes Offering
Surgery Partners, Inc. announced that its subsidiary, Surgery Center Holdings, Inc., priced $425.0 million aggregate principal amount of 7.250% senior unsecured notes due 2032. The offering, expected to close on December 16, 2025, will use net proceeds for general corporate purposes, including repaying outstanding borrowings under its revolving credit facility. These notes are part of the same series as the $800.0 million notes issued in April 2024 and are being offered privately to qualified institutional buyers and non-U.S. persons.
Surgery Partners, Inc. Announces Add-On Senior Notes Offering
Surgery Partners, Inc. announced an add-on offering of $425 million in 7.250% senior notes due 2032. The proceeds from this offering will be used for general corporate purposes, including the repayment of revolving credit facility borrowings. These notes are guaranteed by the issuer's domestic subsidiaries.
Surgery Partners to offer $425 million in senior unsecured notes
Surgery Partners, Inc. (NASDAQ:SGRY) announced plans to offer an additional $425 million in 7.250% senior unsecured notes due 2032 through its subsidiary. The company intends to use the net proceeds for general corporate purposes, including repaying outstanding borrowings under its revolving credit facility. Analysts predict Surgery Partners, which was not profitable last year, will become profitable this year.
Surgery Partners, Inc. Announces Add-On Senior Notes Offering
Surgery Partners, Inc. announced that its wholly-owned subsidiary, Surgery Center Holdings, Inc., plans to offer an additional $425.0 million in 7.250% senior unsecured notes due 2032. The proceeds from this offering are intended for general corporate purposes, including the repayment of outstanding borrowings under its revolving credit facility. The notes will be offered to "qualified institutional buyers" and non-U.S. persons outside the United States.
Surgery Partners, Inc. Plans Offering of $425 Million in Senior Unsecured Notes Due 2032
Surgery Partners, Inc. announced plans to offer an additional $425 million in 7.250% senior unsecured notes due 2032 through its subsidiary, Surgery Center Holdings, Inc. The proceeds from this offering will be used for general corporate purposes, including debt repayment. The notes, which are guaranteed by domestic subsidiaries, are being offered to qualified institutional buyers and non-U.S. persons and will not be registered under the Securities Act.
